Merck’s head of R&D Dean Li believes he’s outfoxed his competition for the next generation of oncology drugs, ...
Vertex, Kindeva and Convatec pledge £1B+ for UK sites in Healey’s first Budget; Teva closes NJ plant; Regeneron extends ...
Eli Lilly once again dominated revenue expectations, blowing past Wall Street’s estimates by about $2 billion.
AI agents are booking medical appointments & fighting insurance denials. Zocdoc welcomes agents; General Medicine designs ...
Dren Bio raises $350M to advance blood cancer drug dibotatug toward 2027 market launch, backed by Juvia Group and Lightspeed ...
FDA releases CRISPR medicine framework for personalized gene therapies, building on Baby KJ's case. Danaher's Kassim flags ...
HHS on Wednesday said it will stop enforcing a ban on the compounding of certain popular peptides used for wellness purposes while the FDA works on rulemaking to address the substances ...
Formation Bio, an AI-focused biotech that acquires outside assets, develops them and then hands them off, has raised ...
Pfizer’s flood-damaged Gujarat cancer drug plant won’t resupply until 2028, deepening US chemotherapy shortages, ASHP said.
Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...
Astellas takes an option on Audax’s preclinical IL-12 drug DAX-044 for $285M upfront and option fees, plus up to $1.05B in ...
Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results